DexCom, Inc. (NASDAQ:DXCM) Stock Rated "Buy" by Sell-Side Analysts

Key Points

• Analyst sentiment is broadly positive: 28 firms rate DexCom a consensus “Buy”—24 Buy, two Strong Buy, and two Hold. The average 12-month price target is $95.50, with recent targets ranging as high as $120.
• Latest quarterly results beat estimates: DexCom reported EPS of $0.73 versus $0.68 expected and revenue of $1.34 billion versus $1.33 billion; revenue grew 11.1% year over year.
• Shares opened at $83.33, and company insiders sold 22,822 shares worth about $1.92 million in the last quarter; the disclosed sales were made under pre-arranged trading plans.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) has been given a consensus rating of "Buy" by the twenty-eight ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, twenty-four have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $95.50.

A number of equities research analysts have recently weighed in on DXCM shares. Royal Bank Of Canada reiterated an "outperform" rating and issued a $105.00 price target (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Robert W. Baird set a $105.00 target price on DexCom and gave the stock an "outperform" rating in a research report on Friday, July 31st. Canaccord Genuity Group raised their target price on DexCom from $90.00 to $97.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Barclays upped their price target on shares of DexCom from $115.00 to $120.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th.

DexCom Price Performance

DXCM opened at $83.33 on Friday. The company has a 50-day moving average of $84.30 and a 200-day moving average of $75.21. The company has a market capitalization of $31.08 billion, a P/E ratio of 32.68, a PEG ratio of 1.34 and a beta of 1.45. DexCom has a 1-year low of $56.72 and a 1-year high of $92.59. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.05. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. During the same quarter in the prior year, the business posted $0.61 EPS. The company's revenue for the quarter was up 11.1% on a year-over-year basis. Equities analysts expect that DexCom will post 2.68 EPS for the current fiscal year.

Insider Activity

In related news, EVP Jereme Sylvain sold 3,638 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the transaction, the executive vice president directly owned 146,828 shares of the company's stock, valued at $12,226,367.56. This represents a 2.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $549,537.56. Following the completion of the sale, the director owned 29,293 shares in the company, valued at approximately $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,822 shares of company stock worth $1,920,193 in the last quarter. Company insiders own 0.28% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DXCM. Latitude Advisors LLC bought a new stake in shares of DexCom during the third quarter valued at about $32,000. Hilton Head Capital Partners LLC increased its stake in DexCom by 242.3% during the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company's stock valued at $33,000 after buying an additional 269 shares during the period. Wellington Grp LLC raised its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock worth $34,000 after buying an additional 475 shares in the last quarter. Elevation Wealth Partners LLC raised its position in shares of DexCom by 61.0% during the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company's stock worth $35,000 after buying an additional 152 shares in the last quarter. Finally, GK Wealth Management LLC bought a new stake in shares of DexCom during the 3rd quarter worth about $35,000. Institutional investors own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company's products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.